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SPIO-Enhanced MRI Findings of 
Well-Differentiated Hepatocellular
Carcinomas: Correlation with MDCT
Findings 
Objective: This study was designed to assess superparamagnetic iron oxide
(SPIO)-enhanced MRI findings of well-differentiated hepatocellular carcinomas
(HCCs) correlated with their multidetector-row CT (MDCT) findings.
Materials and Methods: Seventy-two patients with 84 pathologically proven
well-differentiated HCCs underwent triple-phase MDCT and SPIO-enhanced MRI
at a magnetic field strength of 1.5 Tesla (n = 49) and 3.0 Tesla (n = 23). Two radi-
ologists in consensus retrospectively reviewed the CT and MR images for attenu-
ation value and the signal intensity of each tumor. The proportion of hyperintense
HCCs as depicted on SPIO-enhanced T2- or T2*-weighted images were com-
pared in terms of tumor size (< 1 cm and > 1 cm), five CT attenuation patterns
based on arterial and equilibrium phases and magnetic field strength, by the use
of univariate and multivariate analyses.
Results: Seventy-eight (93%) and 71 (85%) HCCs were identified by CT and
on SPIO-enhanced T2- and T2*-weighted images, respectively. For the CT atten-
uation pattern, one (14%) of seven isodense-isodense, four (67%) of six hypo-
dense-hypodense, four (80%) of five isodense-hypodense, 14 (88%) of 16 hyper-
dense-isodense and 48 (96%) of 50 hyperdense-hypodense HCCs were hyperin-
tense (Cochran-Armitage test for trend, p < 0.001). Based on the use of multivari-
ate analysis, the CT attenuation pattern was the only factor that affected the pro-
portion of hyperintense HCCs as depicted on SPIO-enhanced T2- or T2*-weight-
ed images (p < 0.001). Tumor size or magnetic field strength was not a factor that
affected the proportion of hyperintense HCCs based on the use of univariate and
multivariate analysis (p > 0.05).
Conclusion: Most well-differentiated HCCs show hyperintensity on SPIO-
enhanced MRI, although the lesions show various CT attenuation patterns. The
CT attenuation pattern is the main factor that affects the proportion of hyperin-
tense well-differentiated HCCs as depicted on SPIO-enhanced MRI.
ith the use of advanced imaging technologies and regular follow-up
examinations, many hepatic nodules including nonmalignant regenerative
and dysplastic nodules or hepatocellular carcinomas (HCCs) are detected
during the course of chronic liver disease (1, 2). In clinical practice, it is important to
detect HCCs at the early stage (when the tumors are well differentiated) and to distin-
guish a well-differentiated HCC from a nonmalignant lesion such as a regenerative and
dysplastic nodule. Diagnosis of HCC in the early stage and surgical resection of the
tumor or transplantation of the liver substantially increase patient survival (3).
However, there is considerable overlap of computed tomography (CT) (2, 4-10) and
magnetic resonance imaging (MRI) (9, 11-21) appearances of prominent regenerative
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Wnodules, dysplastic nodules and well-differentiated HCCs.
Multiphasic multidetector row CT (MDCT) and
superparamagnetic iron oxide (SPIO)-enhanced MRI are
clinically useful modalities to diagnose HCCs (9, 14). The
malignant tumors usually lack Kupffer cells and appear to
be hyperintense against the hypointense background of the
surrounding normal hepatic parenchyma (9, 11-21).
However, limitations of the use of SPIO for the detection
of well-differentiated HCCs have been reported due to the
retained Kupffer cell activity within the tumor (9, 11-21).
To the best of our knowledge, there have been several
studies that have evaluated the enhancement pattern and
clinical usefulness of MDCT and SPIO-enhanced MRI for
well-differentiated HCCs (5, 13-16, 22, 23). However,
only a limited number of well-differentiated HCCs have
been analyzed with the use of resected specimens as the
reference standard. There are also no published studies
that have compared imaging obtained at 1.5 Tesla (T) and
3.0 T magnetic field strengths with regard to SPIO-
enhanced MRI for the evaluation of a well-differentiated
HCC. Therefore, the purpose of this study was to assess
SPIO-enhanced MRI findings of well-differentiated HCCs,
which were proven by surgical resection, in association
with MDCT findings and magnetic field-strength.
MATERIALS AND METHODS
Patients
The institutional review board approved this retrospec-
tive study, and the requirement for patient informed
consent was waived. Between January 2000 and August
2007, we reviewed the histopathological reports of hepatic
resected specimens at our institution. The usual criteria for
selecting a patient for partial hepatic resection surgery
were the following; the presence of one or more tumors of
any size that showed hyperintensity on SPIO-enhanced
MRI irrespective of the CT enhancement pattern, or
hypervascular masses or prominent nonhypervascular
masses > 2 cm in diameter depicted on CT despite SPIO
uptake with a limited location to one lobe of the liver; and
Child-Pugh class A function in patients suspected of having
HCC with an elevated α -fetoprotein level. A total of 122
patients with 154 well-differentiated HCCs were identi-
fied. In our institution, for patients suspected of having
HCC, SPIO-enhanced MRI was usually performed for the
detailed preoperative staging work-up after a multiphasic
CT examination or was performed to determine whether
prominent hepatic nodules with slow growth that did not
show typical CT enhancement of an HCC were or were
not malignant. Of the 122 patients, 50 patients were
excluded from the study because either a CT examination
or SPIO-enhanced MRI was not performed. Finally, 72
consecutive patients (67 men and five women; age range,
33-81 years; mean age, 59 years) with 84 well-differenti-
ated HCCs were enrolled in the study who were examined
with both triple-phase MDCT and SPIO-enhanced MRI. Of
these 72 patients, six patients had two well-differentiated
HCCs and two patients had three and five well-differenti-
ated HCCs, respectively, based on histopathology. Hepatic
resection surgery was performed within four weeks after
the imaging studies.
Histopathological Examination
For the diagnosis of well-differentiated HCCs in our
institution, the resected specimens were serially sliced with
a 5-mm thickness in the transverse or coronal plane,
depending on the location of the tumor. One experienced
pathologist analyzed the histological grade of the tumor
according to the grading system of Edmondson and Steiner
(24). A well-differentiated HCC corresponded to
Edmondson-Steiner grade I. HCCs consisting mostly of
Edmondson-Steiner grade I with a minimal-to-small
portion of Edmondson-Steiner grade II were also
diagnosed as well-differentiated HCCs, based on the
predominant histological characteristics (25).
In our study, the tumors ranged from 0.1 to 11 cm in
diameter (mean, 2.2 cm). Based on histological evaluations
of the background liver in the resected specimens, 39 and
24 patients had liver cirrhosis and chronic hepatitis, respec-
tively. Of these patients, 45 patients were infected with
hepatitis B, 17 patients were infected with hepatitis C and
one patient suffered from alcoholism. Nine patients had a
normal liver. The patients with liver cirrhosis showed
clinically Child-Pugh class A liver function.
Imaging Methods
Triple-phase helical CT examinations were performed
using MDCT scanners with four (LightSpeed QX/I; GE
Healthcare, Milwaukee, WI) (n = 27), eight (LightSpeed
Ultra 8; GE Healthcare) (n = 15), 16 (LightSpeed 16; GE
Healthcare) (n = 18), 40 (Brilliance 40; Philips Medical
Systems, Eindhoven, The Netherlands) (n = 7) and 64
detector rows (Aquilion 64; Toshiba Medical, Tokyo,
Japan) (n = 5). The scanning parameters were 120 kVp,
175-184 mAs, 5-mm slice thickness, a table speed of 15.0-
53.0 mm/rotation (pitch of 0.75-0.938) and a single breath
hold helical acquisition of 5-12 seconds (depending on
liver size). Images were obtained in the craniocaudal
direction and were reconstructed every 5 mm to provide
contiguous sections. Hepatic arterial phase scanning began
30-35 seconds after injection of 120 mL of a nonionic
iodinated contrast material (iopamidol, Iopamiro 300;
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triggered technique. The contrast material was injected
through the antecubital vein using a power injector. The
portal and equilibrium phases of scanning began 70
seconds and 180 seconds after injection of the contrast
material, respectively.
MRI was performed with a 1.5 T (Signa Horizon; GE
Healthcare) (n = 49) and a 3.0 T whole-body MR system
(Intera Achieva 3.0 T; Philips Medical Systems) (n = 23)
within 15 days after the CT examination. Ferumoxides
(Feridex IV; Advanced Magnetics, Cambridge, MA) and
Ferucarbotran (Resovist; Schering, Berlin, Germany) were
used in 21 and 51 patients, respectively, as SPIO agents.
Ferumoxides solution at a dose of 15 μ mol per kilogram of
body weight diluted in 100 mL of 5% glucose solution was
infused through a 5-μ m specific filter for approximately 30
minutes. MRI was initiated 30 minutes after the end of the
infusion. The dose of ferucarbotran was 1.4 mL in patients
with a body weight of 60 kg or more and a dose of 0.9 mL
in patients with a body weight of less than 60 kg (dose
range, 8.0-12.0 μ mol iron/kg). The contrast agent was
manually administered IV through an in-line 5-μ m specific
filter with a rapid bolus in 1 second, immediately followed
by a 10-mL saline solution flush. The entire procedure was
performed in approximately 5 seconds. MRI was initiated
ten minutes after the injection of the contrast agent.
All images were obtained in the axial plane with a
phased-array multicoil for the body, a 6-8 mm section
thickness (according to the liver volume) with a 2 mm
intersection gap for 1.5 T MR and a 5-7 mm section
thickness with a 1-mm to 2-mm intersection gap for 3.0 T
MR and a field of view of 32-38 cm. Saturation bands
superior and inferior to the imaging volume were applied
in all sequences to minimize motion artifacts that arose
from vessels.
After the injection of the contrast agent, the MRI
protocol included a fat-suppressed respiratory-triggered
T2-weighted fast spin-echo sequence (TR/TE, 3,333-
8,571/90-117 msec; an echo train length of 10-18; a 256
×256 matrix; a bandwidth of 120 Hz per pixel) and a T2*-
weighted fast multiplanar gradient-recalled echo acquisi-
tion in the steady state (TR/TE range, 130/8.4-10.4 msec;
flip angle, 30� ; bandwidth of 60 Hz per pixel) for 1.5 T
MR. For 3.0 T MR, a fat-suppressed breath hold multi-shot
T2-weighted sequence with a reduction factor of two or
four (TR/TE, 2,161/70 msec; flip angle, 90� ; matrix, 400 ×
280; bandwidth of 235.2 Hz per pixel) and a T2*-weighted
fast field-echo sequence (TR/TE, 129/9.2 msec; flip angle,
20� ; matrix, 224×179; bandwidth of 289.5 Hz per pixel)
were acquired.
Image Analysis
All of the CT images were interpreted using a 2,000×
2,000 Picture Archiving and Communication System
(PACS; GE Healthcare Integrated Imaging Solutions)
monitor. Two abdominal radiologists (with eight and 21
years experience, respectively) retrospectively analyzed
the CT and MR images by consensus. The radiologists had
knowledge that the patients had HCCs with their segmen-
tal location (Couinaud segment), but the radiologists were
blinded to the pathological grades and clinical information
and to the original imaging reports. The radiologists
recorded the size, density on CT images and signal
intensity on MR images for the HCCs. The histopathologi-
cal results of the resected specimens were correlated with
the preoperative imaging findings.
The density on CT images as determined by visual
inspection was considered hyperdense when it was higher
than the surrounding liver, isodense when it was compara-
ble to the surrounding liver and hypodense when it was
lower than the surrounding liver on each phase. A tumor
was categorized as hypervascular, isovascular and
hypovascular based on the pattern of density on contrast-
enhanced arterial-phase CT images. When disagreement
took place between the radiologists, consensus was
achieved by discussion. HCCs were classified into five
categories based on the CT density pattern (isodense-
isodense, hypodense-hypodense, isodense-hypodense,
hyperdense-isodense and hyperdense-hypodense) accord-
ing to the pattern of the density as depicted on the arterial
and equilibrium phases of CT as based on several reports
(26, 27). The typical enhancement pattern of an HCC was
defined as a hyperdense-hypodense pattern based on a
previous report (14). The portal phase was not considered
for the evaluation of CT density pattern, as many HCCs
are not conspicuous on this phase. The signal intensity on
MR images was considered hyperintense when the signal
intensity of an HCC was higher than the surrounding liver,
isointense when the signal intensity was comparable to the
surrounding liver and hypointense when the signal
intensity was lower than the surrounding liver as depicted
on SPIO-enhanced T2-weighted and/or T2*-weighted
images. When the signal intensity of an HCC was hyperin-
tense to the surrounding liver as depicted on SPIO-
enhanced T2-weighted and/or T2*-weighted images, the
HCC was considered as having an impaired Kupffer cell
number or activity for the uptake of SPIO. When the signal
intensity of HCC was isointense or hypointense to the
surrounding liver as depicted on both SPIO-enhanced T2-
weighted and T2*-weighted images, the HCC was consid-
ered to have taken up SPIO.
The tumors, which were not identified on contrast-
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images, were regarded to be isodense or isointense.
We evaluated the proportion of hyperintense HCCs
based on tumor size and the five categories of the CT
density patterns. In addition, we compared the proportion
of hyperintense HCCs with the use of 1.5 T and 3.0 T MR
imaging.
Statistical Analysis
The differences of mean tumor sizes were compared
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Fig. 1. 61-year-old woman with 0.5-cm well-differentiated hepatocellular carcinoma in segment VII.
A, B. Contrast-enhanced CT scans obtained at arterial (A) and equilibrium (B) phases show small nodule with hypodense-hypodense
pattern (arrows), which mimics nonmalignant nodule such as regenerative or dysplastic nodule. Small hypodense lesion (arrowhead in
B) in left liver is part of cyst.
C. Ferucarbotran-enhanced T2*-weighted fast field-echo (TR/TE, 129/9.2 msec; flip angle, 20� ) axial image obtained at 3.0 T shows
small hyperintense nodule (arrow). Small hyperintense lesion (arrowhead) in left liver is part of cyst.
ABC
Fig. 2. 57-year-old man with 1.9-cm well-differentiated hepatocellular carcinoma in segment V.
A, B. Contrast-enhanced CT scans obtained at arterial (A) and equilibrium (B) phases show small nodule with isodense-hypodense
pattern (arrows).
C. Ferucarbotran-enhanced T2*-weighted fast field-echo (TR/TE, 129/9.2 msec; flip angle, 20� ) axial image obtained at 3.0 T shows
discrete hyperintense nodule (arrow).
ABCusing the Mann-Whitney U test. The differences of the
proportion of hyperintense HCCs according to the tumor
size (< 1 cm and > 1 cm) and magnetic field-strength were
compared using Fisher’s exact test. Statistical analysis for
trend for the proportion of hyperintense HCCs on SPIO-
enhanced MRI according to the five CT density patterns
was assessed using the Cochran-Armitage test. Multivariate
analysis with multiple logistic regression analysis was used
to analyze factors that affected the proportion of hyperin-
tense HCCs on SPIO-enhanced MRI. A p value of less than
0.05 was considered as statistically significant.
RESULTS
Among 84 well-differentiated HCCs, 78 (93%) (Figs. 1-
4) were identified by CT and 71 (85%) were identified as
hyperintense as seen on SPIO-enhanced T2- and/or T2*-
weighted MR images (Figs. 1, 2).
The proportion of hyperintense HCCs according to the
tumor size and five CT density patterns for well-differenti-
ated HCCs are shown in Table 1. A total of 13 (15%) of
84 HCCs were not hyperintense as seen on SPIO-enhanced
MR images (Figs. 3, 4). The proportion of hyperintense
tumors for HCCs < 1 cm was less than for HCCs > 1 cm,
but the difference was not statistically significant (p =
0.05). A chance to appear as a hyperintense HCC accord-
Kim et al.
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Table 1. Frequency and Percentage of Hyperintense Well-differentiated HCCs Characterized by SPIO-enhanced MRI Based on
Tumor Size and CT Density Pattern
Size
CT Density Pattern
Total
Iso-Iso Hypo-Hypo Iso-Hypo Hyper-Iso Hyper-Hypo
< 1 cm 0/4 (0)0 1/1 (100) 1/1 (100) 01/20 (50) 007/70 (100) 10/15 (67)
> 1 cm 1/3 (33) 3/5 (60)0 3/4 (75)0 13/14 (93) 41/43 (95) 61/69 (88)
Total 1/7 (14) 4/6 (67)0 4/5 (80)0 14/16 (88) 48/50 (96) 71/84 (85)
Note.─ Numbers in parentheses are percentages. Density of tumor on CT was considered hyperdense, isodense and hypodense as compared with that of
surrounding liver on arterial and equilibrium phases, respectively. Iso-Iso = isodense-isodense pattern, Hypo-Hypo = hypodense-hypodense pattern, 
Iso-Hypo = isodense-hypodense pattern, Hyper-Iso = hyperdense-isodense pattern, Hyper-Hypo = hyperdense-hypodense pattern. Signal intensity of
tumor on MR images was considered hyperintense, isointense and hypointense as compared with that of surrounding liver on SPIO-enhanced T2-
weighted and/or T2*-weighted images. Thirteen well-differentiated HCCs were isointense as depicted on SPIO-enhanced T2-weighted and T2*-weighted
images. HCC = hepatocellular carcinoma, SPIO = superparamagnetic iron oxide
Fig. 3. 48-year-old man with 2.3-cm well-differentiated hepatocellular carcinoma in segment VI.
A, B. Contrast-enhanced CT scans obtained at arterial (A) and equilibrium (B) phases show nodule with hyperdense-isodense pattern
(arrows).
C. As seen on ferucarbotran-enhanced T2*-weighted fast multiplanar gradient-recalled echo axial image (TR/TE range, 130/8.4 msec;
flip angle, 30� ) obtained at 1.5 T, nodule as seen on CT image does not appear to be hyperintense.
ABCing to the five CT density patterns tended to increase from
the isodense-isodense pattern to the hyperdense-
hypodense pattern as shown in Table 1 (p < 0.001).
Seventy (91%) of 77 HCCs that did not show the
isodense-isodense pattern were hyperintense (Figs. 1, 2).
Sixty-two (94%) of 66 hypervascular HCCs were hyperin-
tense. In contrast, nine (50%) of 18 nonhypervascular
HCCs were hyperintense. Twenty-three (68%) of 34
HCCs with an atypical enhancement pattern were hyperin-
tense as seen on SPIO-enhanced MRI.
Based on the magnetic field strength, the mean tumor
size in 49 patients with 58 HCCs examined with 1.5 T MR
(range, 0.4-11.0 cm in diameter; mean ± standard
deviation [SD], 2.5 ± 2.0 cm) was significantly larger than
that (range, 0.1-3.8 cm; mean ± SD, 1.6 ± 0.8 cm) of 23
patients with 26 HCCs examined with 3.0 T MR (p =
0.049). In patients examined with 1.5 T MR, 48 (83%)
HCCs were hyperintense, and this result was not signifi-
cantly different for 23 HCCs (88%) that were hyperin-
tense as examined on 3.0 T MR (p = 0.745).
Based on the use of multiple logistic regression analysis,
the CT density pattern was the only factor that affected the
proportion of hyperintense HCCs as seen on SPIO-
enhanced T2- or T2*-weighted images (p < 0.001). Tumor
size (p = 0.391) and magnetic field strength (p = 0.149)
were not statistically significant.
DISCUSSION
Based on multistep hepatocarcinogenesis, HCCs are
thought to develop from a regenerative nodule to a
dysplastic nodule, subsequently into a well-differentiated
HCC and ultimately to an advanced tumor such as a
moderately and poorly differentiated HCC (28, 29). The
biological aggressiveness of a well-differentiated HCC as
an early stage of HCC in hepatocarcinogenesis is unclear,
but it is considered to have a relatively low malignant
potential and rarely invades vessels or metastasizes to
other sites (30).
In our study, 15% of well-differentiated HCCs were not
hyperintense as depicted on both SPIO-enhanced T2- and
T2*-weighted MR images, which was lower than 23-85%
reported in several previous studies (13-16) and was
comparable to 17% reported in another previous study
(20).
Our study showed that the proportion of hyperintense
well-differentiated HCCs tended to be higher in tumors > 1
cm than in tumors < 1 cm and in hypervascular tumors
rather than non-hypervascular tumors. This result may
suggest that a decrease in the Kupffer cell number and
function occurs in parallel with an alteration in tumor size
and tumor vascularity in HCCs, as has been reported
previously (11, 13).
It is known that sinusoidal capillarization and an increase
in the number of unpaired arteries appear to be detectable
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Fig. 4. 64-year-old man with 1.6-cm well-differentiated hepatocellular carcinoma in segment VI.
A, B. Contrast-enhanced CT scans obtained at arterial (A) and equilibrium (B) phases show small nodule with hyperdense-hypodense
pattern (arrows).
C. As seen on ferucarbotran-enhanced T2*-weighted fast multiplanar gradient-recalled echo axial image (TR/TE range, 130/8.4 msec;
flip angle, 30� ) obtained at 1.5 T, nodule as seen on CT image does not appear to be hyperintense.
ABClate as “hypervascularity” on imaging (21). With the
advantages of MDCT such as a rapid scanning time and
thinner section collimation with higher temporal and
spatial resolution, as demonstrated in our study, MDCT
showed a higher percentage (79%) of hypervascular well-
differentiated HCCs as compared with 47% in a previous
study with the use of single-detector CT (6). However,
21% of the well-differentiated HCCs in our study
appeared isovascular or hypovascular on the arterial phase
probably due to less neoplastic angiogenesis and
incomplete vascularization of the sinusoid-like blood
spaces of the tumor (4-6), a finding that overlaps with the
imaging findings of nonmalignant nodules such as regener-
ative and dysplastic nodules.
It is believed that well-differentiated HCCs with
decreased portal tracts without increased abnormal arteries
are hypodense as seen on the arterial phase, and when the
increased abnormal arterial supply compensates for a
decreased arterial supply through the portal tracts, the
HCCs are visualized as isodense on the arterial phase. The
isodense or hypodense HCCs on the arterial phase with
decreased portal tracts appear to be hypodense on the
equilibrium phase. In our study, the chance to appear as a
hyperintense HCC according to the five CT density
patterns tended to increase from the isodense-isodense
pattern to the hyperdense-hypodense pattern. We believe
that HCCs with an isodense-isodense pattern might have
almost the same arterial and portal supply from portal
tracts similar to the surrounding liver, resulting in a
preserved Kupffer cell number and function. For lesions
with the hyperdense-hypodense pattern, HCCs might have
progressed to a more malignant form than HCCs with an
isodense-isodense pattern, resulting in an impaired Kupffer
cell number and function. Our study showed that 91% of
well-differentiated HCCs that did not show the isodense-
isodense pattern were hyperintense as seen on SPIO-
enhanced MRI, which was comparable to 100% reported
in a previous study (14). We think that if well-differenti-
ated HCCs appear with the four density patterns other
than the isodense-isodense pattern, which may not be
recognized on imaging, the HCCs may have a high chance
to be detected as a hyperintense nodule due to the
impaired Kupffer cell activity on SPIO-enhanced MRI.
A previous study (13) has reported that none of eight
non-hypervascular well-differentiated HCCs was hyperin-
tense as seen on SPIO-enhanced MRI. In our study, 50%
of non-hypervascular well-differentiated HCCs were
hyperintense. The reason for the difference is unclear, but
may be due to a different study population and design.
Some investigators have suggested that SPIO-enhanced
MRI might reflect functional and histological changes of
tumors that can be present and detectable in advance as
compared to arterial hypervascularization (21), which
supports our results. However, as 50% of non-hypervascu-
lar well-differentiated HCCs were not hyperintense, the
differentiation between these tumors and benign nodules
such as regenerative and dysplastic nodules remains
challenging. Therefore, for these nodules, a biopsy is
needed, if possible.
In clinical practice, the diagnosis of an HCC is limited to
nodules with a typical enhancement pattern (hypervascular
with washout on the portal and/or equilibrium phase) (31).
Although our study showed that the ability of MDCT to
identify hypervascular and hypovascular well differenti-
ated HCCs is excellent with the use of triple-phase MDCT,
as has been reported previously (4-6), CT enhancement
patterns of well-differentiated HCCs are diverse and a
diagnosis by MDCT alone may be inconclusive. In our
study, 68% of well-differentiated HCCs with an atypical
enhancement pattern were hyperintense as seen on SPIO-
enhanced MRI. Based on the results, we believe that SPIO-
enhanced MRI may be utilized as a problem-solving tool
with increased diagnostic confidence in cases of suspected
well-differentiated HCCs that show atypical CT findings.
One study (32) reported that the diagnostic accuracy for
detection of malignant hepatic lesions with the use of 1.5 T
and 3.0 T on SPIO-enhanced MRI were equivalent, which
supports our results that showed no significant difference
for the detection of hyperintense well-differentiated HCCs
between the use of these magnetic field strengths on SPIO-
enhanced MRI.
We recognize some limitations of this study. First, the
enrolled patients were collected for a long period with the
use of various imaging parameters and MR contrast agents,
which may affect the CT enhancement pattern and signal
intensity of well-differentiated HCCs. However, we think
that the various CT scanners and MR contrast agents that
were utilized minimally influenced the CT enhancement
pattern and signal intensity on SPIO-enhanced MRI, as
arterial phase CT images using a bolus-triggered technique
and recommended accumulation phase MR images after
the injection of different MR contrast agents were
constantly acquired during the examination. Second, only
patients with pathologically proven well-differentiated
HCCs obtained exclusively after surgical resection as the
standard of reference were enrolled in the study, which
may be one possible reason for a higher proportion of
hyperintense well-differentiated HCCs as compared with
previous studies (13-16). Third, the study population had
well-preserved liver function. However, the effect of SPIO
to increase the tumor-to-liver contrast-to-noise ratio may
not be sufficiently strong in a severely cirrhotic liver,
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ated HCC.
In conclusion, most (85%) well-differentiated HCCs
showed hyperintensity on SPIO-enhanced MRI, although
the well-differentiated HCCs showed various CT density
patterns. The CT density pattern was the main factor that
affected the proportion of hyperintense well-differentiated
HCCs as depicted on SPIO-enhanced MRI.
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